Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Breastcancer.org Podcast

SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?

21 Apr 2020

Description

Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care. Listen to the episode to hear Dr. Murthy explain: a summary of the study results why this study included people with brain metastases the side effects of tucatinib why she thinks the results are practice changing

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.